Medicine and Dentistry
Cystectomy
100%
Bladder Cancer
83%
Prostate Cancer
78%
Systematic Review
62%
Muscle Invasive Bladder Cancer
51%
Prostatectomy
47%
Neoadjuvant Chemotherapy
46%
Robot-Assisted Prostatectomy
43%
Meta-Analysis
31%
Biopsy Technique
31%
Malignant Neoplasm
31%
Biological Marker
29%
COVID-19
26%
Urinary System
22%
Neoplasm
21%
Pneumoperitoneum
20%
Transurethral Resection
20%
Disease
19%
Non Muscle Invasive Bladder Cancer
19%
Bladder
19%
Computer Assisted Tomography
18%
positron emission tomographic scan
18%
Operation Duration
16%
Pelvis
16%
Surgery
16%
Urology
16%
Robot-Assisted Surgery
16%
Prostate Biopsy
15%
Diagnosis
15%
Surgeon
15%
Overall Survival
15%
Urinary Tract Cancer
15%
Pandemic
15%
Urinary Diversion
15%
Smoke
14%
Microhematuria
14%
Cystoscopy
13%
Adenocarcinoma
13%
Transrectal Ultrasonography
13%
Chemotherapy
13%
Magnetic Resonance Imaging
13%
Radiation Therapy
12%
Randomized Controlled Trial
12%
Hazard Ratio
12%
Bladder Tumor
12%
Odds Ratio
12%
Da Vinci Surgical System
11%
Prostate Specific Membrane Antigen
11%
Urologic Surgery
11%
Metastatic Carcinoma
11%
Keyphrases
Bladder Cancer
86%
Radical Cystectomy
62%
Muscle-invasive Bladder Cancer
51%
Neoadjuvant Chemotherapy
48%
Robot-assisted Radical Cystectomy
47%
Meta-analysis
39%
Robot-assisted Laparoscopic Radical Prostatectomy
35%
Prostate Cancer
34%
Systematic Meta-analysis
31%
Confidence Interval
29%
Robot-assisted Radical Prostatectomy
26%
Non-muscle Invasive Bladder Cancer (NMIBC)
25%
COVID-19
23%
Prostate
21%
Oncological Outcomes
21%
Clinical Outcomes
21%
High Risk
21%
Open Radical Cystectomy
20%
Urological Cancer
20%
Cystectomy
20%
Artificial Intelligence
19%
Neurovascular Unit
18%
Cystoscopy
17%
Radical Prostatectomy
17%
Urinary Biomarkers
17%
PubMed
16%
Overall Survival
16%
COVID-19 Pandemic
16%
Surgeons
16%
Prostate Cancer Screening
16%
Transurethral Resection of Bladder Tumor (TURBT)
15%
Robotic Surgery
15%
Survival Outcomes
15%
Randomized Controlled Trial
14%
Pneumoperitoneum
14%
Intermediate Risk
14%
MEDLINE
14%
Statistic Data
14%
Hospital Episode Statistics
14%
Prostate Biopsy
14%
Frozen Section Diagnosis
14%
Hematuria
14%
Hazard Ratio
13%
Urology
13%
Urine Cytology
13%
Localized Prostate Cancer
13%
FDA-approved Drugs
13%
Odds Ratio
13%
Oncologic
13%
Embase
12%